Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Belrestotug plus dostarlimab showed no progression-free survival benefit in NSCLC, leading GSK and iTeos to discontinue all ...

Fact checked by Jennifer Klump When Maureen Sideris, 71, was diagnosed with gastroesophageal junction cancer in 2022, doctors ...

Teos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 ...

At that time, I noted the potential of the company advancing its anti-TIGIT drug belrestotug together with GSK plc's (GSK) PD-1/PD-L1 JEMPERLI (dostarlimab) for the targeting of previously ...

Belgian clinical-stage biotech iTeos Therapeutics (Nasdaq: ITOS) saw its shar leap18.6% to $8.20 today, despite posting ...

Congress is considering reducing the amount of time that pharmaceutical drugs will be patent protected. Stop and think about ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

This new immunotherapy is particularly effective in several types of solid tumors, but it will take time to confirm its ...

Teos Therapeutics faces significant setbacks with the discontinuation of their TIGIT program and belrestotug, leaving them ...

ITeos Therapeutics shares climbed after the company said it would evaluate strategic alternatives. The stock rose 16% to $8.01 on Tuesday, putting it on track for its largest percent increase in a ...

dostarlimab monotherapy in PD-L1 positive head and neck squamous cell carcinoma. Based on these results, iTeos and GSK have decided to terminate the belrestotug development program and end the ...